Trial Profile

A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 Oral Solution in Patients With Parkinson's Disease of Moderate Severity Responding to Immediate-Release Oral Levodopa/Carbidopa and Withdrawn From Levodopa/Carbidopa

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zuranolone (Primary) ; Catechol O-methyltransferase inhibitors; Dopamine receptor agonists; Levodopa/carbidopa; Monoamine oxidase B inhibitors
Indications Parkinson's disease
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Biogen

02 Nov 2017 Top-line results for Part B published in a Sage Therapeutics Media Release.
20 Oct 2017 Status changed from recruiting to completed.
04 Aug 2017 According to a Sage Therapeutics Media Release, Part B study has been initiated.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com